September 17, 2025
2 min watch
In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the potential of tumor necrosis factor-like ligand 1A inhibitors in treating inflammatory bowel disease.
In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the potential of tumor necrosis factor-like ligand 1A inhibitors in treating inflammatory bowel disease.
This class of drugs has shown early promise in both Crohn’s disease and ulcerative colitis.
“This is an interesting mechanism of action because not only is it involved in inflammation, but it may also be involved in the development of fibrosis,” Loftus, the Maxine and Jack Zarrow Family Professor of Gastroenterology at Mayo Clinic and chief medical editor of Healio Gastroenterology, said. “It holds out the possibility that maybe some symptomatic strictures could be medically treated in the future rather than relying on endoscopic dilation or surgical means.”
In this month’s issue of Healio Gastroenterology, experts delve into early clinical trial results that show how TL1A inhibitors could advance precision medicine in IBD.
“One interesting aspect is that there may be biomarkers that could potentially identify patients who are more likely to respond to this class of therapy, which could widen the availability of precision medicine to IBD,” Loftus wrote in an accompanying editorial.
Sources/Disclosures
Collapse
Healio Interviews
Disclosures:
Loftus reports consulting for AbbVie, Alvotech, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Eli Lilly & Co., Fresenius Kabi, Gilead Sciences, Janssen and Takeda, and receiving research support from AbbVie, Bristol Myers Squibb, Celgene/Receptos, Gilead, Janssen and Takeda.
